Robert Lowsky
Academic Appointments
- Associate Professor - Med Center Line, Medicine - Blood & Marrow Transplantation
- Member, Cancer Center
Key Documents
Contact Information
-
Clinical Offices
Blood and Marrow Transplantation 875 Blake Wilbur Dr Clinic E Stanford, CA 94305-5820 Tel Work (650) 723-0822 Fax (650) 725-8950
- Academic Offices
Personal Information Email Tel (650) 723-0822Not for medical emergencies or patient use
Professional Overview
Clinical Focus
- Cancer> Blood and Marrow Transplant
- Cancer> Hematology
- Blood and Marrow Transplantation
- Hematology
Professional Education
| Fellowship: | Toronto General Hospital, Canada (1993) |
| Board Certification: | Internal Medicine, Royal College of Physicians and Surgeons (1992) |
| Residency: | Toronto General Hospital, Canada (1991) |
| Internship: | Toronto General Hospital, Canada (1989) |
| Medical Education: | McGill University, Canada (1988) |
Scientific Focus
Current Research Interests
Dr. Lowsky's research is focused on understanding the role of regulatory T cells in the prevention of GVHD and in promoting immune tolerance following organ transplantation.
Clinical Trials
- Allogeneic HCT using Nonmyeloablative Host Conditioning with TLI & ATG vs SOC in AML Recruiting
- Allogeneic Transplantation Using TL1 & ATG for Older Patients with Hematologic Malignancies Recruiting
- TLI & ATG for Non-Myeloablative Allogeneic Transplantation for MDS and MPD Recruiting
- A Phase 3 Study of Brentuximab Vedotin (SGN-35) for Prevention of Hodgkin Lymphoma Progression (The AETHERA Trial) Recruiting
- Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma Recruiting
Publications
- Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2011; (11): 1679-87
- Donor immunization with WT1 peptide augments antileukemic activity after MHC-matched bone marrow transplantation. Blood. 2011; (19): 5319-29
- Long-term outcomes in patients with high-risk myeloid malignancies following matched related donor hematopoietic cell transplantation with myeloablative conditioning of BU, etoposide and CY. Bone Marrow Transplant. 2011; (2): 192-9
- Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation. Bone Marrow Transplant. 2011
- Translational studies in hematopoietic cell transplantation: treatment of hematologic malignancies as a stepping stone to tolerance induction. Semin Immunol. 2011; (4): 273-81
